Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 76
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT06059118 | Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer | ||
| NCT03276572 | Phase I Trial of 225Ac-J591 in Patients With mCRPC | ||
| NCT04343885 | In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy | ||
| NCT02499835 | Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer | ||
| NCT00156884 | A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer | ||
| NCT02985021 | Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies | ||
| NCT02159690 | A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy | ||
| NCT03007732 | Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT | ||
| NCT06040125 | Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial | ||
| NCT05078151 | Whole-Body Diffusion-Weighted Magnetic Resonance Imaging (MRI) as a Response Biomarker for Metastatic Prostate Cancer | ||
| NCT02269982 | Prospective CiRculating prOstate Cancer Predictors in HighEr Risk mCRPC studY | ||
| NCT04447703 | Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET Study | ||
| NCT03644303 | Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients. | ||
| NCT05765500 | RecoverPC: Relugolix vs GnRH Agonist in Quality of Life | ||
| NCT02881242 | Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer | ||
| NCT03031821 | Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome | ||
| NCT05320406 | RElugolix VErsus LeUprolide Cardiac Trial | ||
| NCT03957252 | Validation of ClarityDX Prostate as a Reflex Test to Refine the Prediction of Clinically-significant Prostate Cancer | ||
| NCT06171139 | Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer | ||
| NCT00953576 | Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer | ||
| NCT06126731 | Combination Study of Antibiotics With Enzalutamide (PROMIZE) | ||
| NCT05355727 | PROSAIC-DS Study (PROState AI in Cancer - Decision Support) | ||
| NCT05113537 | Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer | ||
| NCT05041504 | A Web-based Peer Navigation Program for Men With Prostate Cancer | ||
| NCT01990196 | Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer | ||
| NCT06424275 | Prostate Cancer Awareness and Initiative for Screening in the European Union | ||
| NCT03392428 | A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer | ||
| NCT01961713 | Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy | ||
| NCT07002320 | Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer | ||
| NCT00744549 | Study of Antioxidants on MRI Detectable Early Stage Prostate Cancer Among Men on Active Surveillance | ||
| NCT04116775 | Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer. | ||
| NCT06200974 | Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer | ||
| NCT04430192 | Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy | ||
| NCT05445609 | Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer | ||
| NCT02135484 | Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases | ||
| NCT06616597 | Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer | ||
| NCT04457232 | Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation | ||
| NCT05766371 | Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer | ||
| NCT03440554 | Non-contrast MR Imaging for Whole Body Cancer Detection and Characterization | ||
| NCT06046040 | TmPSMA-02 in mCRPC | ||
| NCT03532217 | Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer | ||
| NCT06714630 | The PROSECCA Study, Answering New Questions in Prostate Cancer | ||
| NCT05150236 | EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC | ||
| NCT03805594 | 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | ||
| NCT06305598 | Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer | ||
| NCT05435495 | Mechanisms of Resistance to PSMA Radioligand Therapy | ||
| NCT06449664 | Training for Men Undergoing Androgen Deprivation Therapy. | ||
| NCT02735252 | PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer | ||
| NCT05918263 | Exercise for Tumor Suppressive Impact in Men With Prostate Cancer at High-Risk of Progression on Active Surveillance: The REMOVE Trial | ||
| NCT02856100 | Comparison of PSMA-based 18F-DCFPyL PET/CT to Conventional Imaging in the Evaluation of Patients With Castration-Resistant Prostate Cancer |
